04 Nov 21:23
by Bloch E, Sikorski EL, Pontoriero D, Day EK, Berger BW, Lazzara MJ, Thévenin D
Disrupting the transmembrane domain-mediated oligomerization of protein tyrosine phosphatase receptor J inhibits EGFR-driven cancer cell phenotypes.
J Biol Chem. 2019 12 06;294(49):18796-18806
Authors: Bloch E, Sikorski EL, Pontoriero D, Day EK, Berger BW, Lazzara MJ, Thévenin D
Abstract
Receptor protein tyrosine phosphatases (RPTPs) play critical regulatory roles in mammalian signal transduction. However, the structural basis for the regulation of their catalytic activity is not fully understood, and RPTPs are generally not therapeutically targetable. This knowledge gap is partially due to the lack of known natural ligands or selective agonists of RPTPs. Contrary to what is known from structure-function studies of receptor tyrosine kinases (RTKs), RPTP activities have been reported to be suppressed by dimerization, which may prevent RPTPs from accessing their RTK substrates. We report here that homodimerization of protein tyrosine phosphatase receptor J (PTPRJ, also known as DEP-1) is regulated by specific transmembrane (TM) residues. We found that disrupting these interactions destabilizes homodimerization of full-length PTPRJ in cells, reduces the phosphorylation of the known PTPRJ substrate epidermal growth factor receptor (EGFR) and of other downstream signaling effectors, antagonizes EGFR-driven cell phenotypes, and promotes substrate access. We demonstrate these observations in human cancer cells using mutational studies and identified a peptide that binds to the PTPRJ TM domain and represents the first example of an allosteric agonist of RPTPs. The results of our study provide fundamental structural and functional insights into how PTPRJ activity is tuned by TM interactions in cells. Our findings also open up opportunities for developing peptide-based agents that could be used as tools to probe RPTPs' signaling mechanisms or to manage cancers driven by RTK signaling.
PMID: 31676686 [PubMed - indexed for MEDLINE]
08 Oct 19:22
by Weiß E, Schlatterer K, Beck C, Peschel A, Kretschmer D
Formyl-peptide receptor activation enhances phagocytosis of community-acquired methicillin-resistant Staphylococcus aureus.
J Infect Dis. 2019 Oct 01;:
Authors: Weiß E, Schlatterer K, Beck C, Peschel A, Kretschmer D
Abstract
Formyl-peptide receptors (FPRs) are important pattern recognition receptors that sense specific bacterial peptides. FPRs are highly expressed on neutrophils and monocytes, and their activation promotes the migration of phagocytes to sites of infection. It is currently unknown, if FPRs may also influence subsequent processes such as bacterial phagocytosis and killing. Staphylococcus aureus, especially highly pathogenic community-acquired methicillin-resistant S. aureus (MRSA) strains, release high amounts of FPR2 ligands, the phenol-soluble modulins (PSMs). We demonstrate that FPR activation leads to upregulation of complement receptors 1 and 3 as well as FCγ receptor I on neutrophils and, consequently, increased opsonic phagocytosis of S. aureus and other pathogens. Increased phagocytosis promotes killing of S. aureus and IL-8 release by neutrophils. We show here for the first time that FPRs govern opsonic phagocytosis. Manipulation of FPR2 activation could open new therapeutic opportunities against bacterial pathogens.
PMID: 31573600 [PubMed - as supplied by publisher]
22 Oct 16:58
by Carlo Matera, Alexandre M. J. Gomila, Núria Camarero, Michela Libergoli, Concepció Soler, Pau Gorostiza

Journal of the American Chemical Society
DOI: 10.1021/jacs.8b08249
22 Oct 16:58
by Hong Yee Tan, Razieh Eskandari, David Shen, Yanping Zhu, Ta-Wei Liu, Lianne Willems, Matthew G. Alteen, Zarina Madden, David J. Vocadlo

Journal of the American Chemical Society
DOI: 10.1021/jacs.8b08260
22 Oct 16:57
by Jiyuan Liu, Li Liu, Zhen Tian, Yifan Li, Changhong Shi, Junling Shi, Sanhua Wei, Yong Zhao, Caiqing Zhang, Bing Bai, Zhinan Chen, Hai Zhang

Molecular Pharmaceutics
DOI: 10.1021/acs.molpharmaceut.8b00996
17 Oct 18:28
by Fabiola Porta, Daniel Ehrsam, Claudia Lengerke, Henriette E. Meyer zu Schwabedissen

Molecular Pharmaceutics
DOI: 10.1021/acs.molpharmaceut.8b00521
17 Oct 18:26
by Michael A. Collier, Robert D. Junkins, Matthew D. Gallovic, Brandon M. Johnson, Monica M. Johnson, Andrew N. Macintyre, Gregory D. Sempowski, Eric M. Bachelder, Jenny P.-Y. Ting, Kristy M. Ainslie

Molecular Pharmaceutics
DOI: 10.1021/acs.molpharmaceut.8b00579
17 Oct 18:25
by Tyler E. Wagner
Small-molecule-based regulation of RNA-delivered circuits in mammalian cells
Small-molecule-based regulation of RNA-delivered circuits in mammalian cells, Published online: 16 October 2018; doi:10.1038/s41589-018-0146-9
Engineering of small-molecule-responsive RNA-binding proteins enables chemical regulation of modified mRNA or RNA replicon expression within mammalian cells for applications in synthetic circuit design and RNA-centered therapeutics.
17 Oct 18:24
by Sammy Pontrelli
Metabolic repair through emergence of new pathways in Escherichia coli
Metabolic repair through emergence of new pathways in <i>Escherichia coli</i>, Published online: 16 October 2018; doi:10.1038/s41589-018-0149-6
In response to the deletion of key genes involved in biosynthesis of the essential CoA precursor β-alanine, Escherichia coli overcomes this pathway damage by successively evolving alternative metabolic pathways.
17 Oct 18:23
by Natalie L. Mutter, Misha Soskine, Gang Huang, Inês S. Albuquerque, Gonçalo J. L. Bernardes, Giovanni Maglia

ACS Chemical Biology
DOI: 10.1021/acschembio.8b00720
15 Oct 13:06
by Martens C, Shekhar M, Borysik AJ, Lau AM, Reading E, Tajkhorshid E, Booth PJ, Politis A
Direct protein-lipid interactions shape the conformational landscape of secondary transporters.
Nat Commun. 2018 10 08;9(1):4151
Authors: Martens C, Shekhar M, Borysik AJ, Lau AM, Reading E, Tajkhorshid E, Booth PJ, Politis A
Abstract
Secondary transporters undergo structural rearrangements to catalyze substrate translocation across the cell membrane - yet how such conformational changes happen within a lipid environment remains poorly understood. Here, we combine hydrogen-deuterium exchange mass spectrometry (HDX-MS) with molecular dynamics (MD) simulations to understand how lipids regulate the conformational dynamics of secondary transporters at the molecular level. Using the homologous transporters XylE, LacY and GlpT from Escherichia coli as model systems, we discover that conserved networks of charged residues act as molecular switches that drive the conformational transition between different states. We reveal that these molecular switches are regulated by interactions with surrounding phospholipids and show that phosphatidylethanolamine interferes with the formation of the conserved networks and favors an inward-facing state. Overall, this work provides insights into the importance of lipids in shaping the conformational landscape of an important class of transporters.
PMID: 30297844 [PubMed - indexed for MEDLINE]
08 Oct 17:16
by Hongting Tang, Zhen Dai, Xuewen Qin, Wenkang Cai, Liming Hu, Yujia Huang, Wenbing Cao, Fan Yang, Chu Wang, Tao Liu

Journal of the American Chemical Society
DOI: 10.1021/jacs.8b06922
08 Oct 17:16
by Yevgeniy V. Serebrenik
CRISPR mutagenesis screening of mice
CRISPR mutagenesis screening of mice, Published online: 08 October 2018; doi:10.1038/s41556-018-0224-y
Functional genetic screening of mice and other mammals is exceedingly challenging. A CRISPR-based mutagenesis screen in mice has successfully revealed amino acids vital for protein function of the DND1 gene, missense mutations of which lead to defects in primordial germ cell development.
08 Oct 15:06
by Miguel F. Sanmamed, Lieping Chen
This Perspective discusses the concept of immune normalization and how its underlying principles may help to augment, as well as design, cancer immunotherapies.
08 Oct 15:05
by Shicheng Su, Jinghua Zhao, Yue Xing, Xiaoqian Zhang, Jiang Liu, Qian Ouyang, Jianing Chen, Fengxi Su, Qiang Liu, Erwei Song
Therapeutic antibody-based cancer treatment leads to ADCP-induced, AIM2-mediated immunosuppression by macrophages that can be overcome with concomitant immune checkpoint blockade.
08 Oct 15:04
by Jianbing Liu,
Linlin Song,
Shaoli Liu,
Shuai Zhao,
Qiao Jiang,
Baoquan Ding
A DNA nanoplatform‐based co‐delivery system containing two linear shRNA transcription templates against tumor‐associated genes (Pgp and survive) and a chemotherapeutic drug (doxorubicin, DOX) was constructed for synergistic therapy of multidrug resistant (MDR) tumors in vivo.
Abstract
Multidrug resistance (MDR) is a major obstacle in the clinical treatment of cancer. Herein, a facile strategy is reported to construct a versatile DNA nanostructure as a co‐delivery vector of RNA interference (RNAi) and chemodrugs to combat multidrug‐resistant tumor (MCF‐7R) in vitro and in vivo. In the tailored nanocarrier, two linear small hairpin RNA (shRNA) transcription templates targeting MDR‐associated genes (gene of P‐glycoprotein, a typical drug efflux pump; and gene of survivin, a representative anti‐apoptotic protein) are precisely organized in the chemodrug (doxorubicin, DOX) pre‐loaded DNA origami. With the incorporation of active targeting and controlled‐release elements, these multifunctional DNA nanocarriers can successfully enter the target MCF‐7R cells and synergistically inhibit tumor growth without apparent systemic toxicity. This tailored DNA nanoplatform, which combines RNAi therapy and chemotherapy, provides a new strategy for the treatment of multidrug‐resistant tumors.
fwn and -1 others like this
08 Oct 15:03
by Beaudoin T, Stone TA, Glibowicka M, Adams C, Yau Y, Ahmadi S, Bear CE, Grasemann H, Waters V, Deber CM
Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms.
Sci Rep. 2018 10 03;8(1):14728
Authors: Beaudoin T, Stone TA, Glibowicka M, Adams C, Yau Y, Ahmadi S, Bear CE, Grasemann H, Waters V, Deber CM
Abstract
With the increasing recognition of biofilms in human disease, the development of novel antimicrobial therapies is of critical importance. For example, in patients with cystic fibrosis (CF), the acquisition of host-adapted, chronic Pseudomonas aeruginosa infection is associated with a decline in lung function and increased mortality. Our objective was to test the in vitro efficacy of a membrane-active antimicrobial peptide we designed, termed 6K-F17 (sequence: KKKKKK-AAFAAWAAFAA-NH2), against multidrug resistant P. aeruginosa biofilms. This peptide displays high antimicrobial activity against a range of pathogenic bacteria, yet is non-hemolytic to human erythrocytes and non-toxic to human bronchial epithelial cells. In the present work, P. aeruginosa strain PAO1, and four multidrug resistant (MDR) isolates from chronically infected CF individuals, were grown as 48-hour biofilms in a static biofilm slide chamber model. These biofilms were then exposed to varying concentrations of 6K-F17 alone, or in the presence of tobramycin, prior to confocal imaging. Biofilm biovolume and viability were assessed. 6K-F17 was able to kill biofilms - even in the presence of sputum - and greatly reduce biofilm biovolume in PAO1 and MDR isolates. Strikingly, when used in conjunction with tobramycin, low doses of 6K-F17 significantly potentiated tobramycin killing, leading to biofilm destruction.
PMID: 30283025 [PubMed - indexed for MEDLINE]
08 Oct 15:03
by Keisuke Tenda,
Benice van Gerven,
Dr. Remco Arts,
Dr. Yuki Hiruta,
Prof. Maarten Merkx,
Prof. Daniel Citterio
Detecting antibodies in blood is as simple as it can get. In their Communication on https://doi.org/10.1002/anie.201808070page 15369 ff., D. Citterio, M. Merkx et al. integrate antibody‐targeting bioluminescent sensing proteins and other essential assay components into a microfluidic paper‐based analytical device. A drop of blood, a digital camera, and twenty minutes are all that is required to detect the presence and the concentration of multiple antibodies in whole blood based on the color of the emitted light.
08 Oct 14:46
by Huan Yao, Hua Ke, Xiaobin Zhang, San-Jiang Pan, Ming-Shuang Li, Liu-Pan Yang, Georg Schreckenbach, Wei Jiang

Journal of the American Chemical Society
DOI: 10.1021/jacs.8b09157
08 Oct 14:45
by Long Li, Ying Jiang, Cheng Cui, Yu Yang, Penghui Zhang, Kimberly Stewart, Xiaoshu Pan, Xiaowei Li, Lu Yang, Liping Qiu, Weihong Tan

Journal of the American Chemical Society
DOI: 10.1021/jacs.8b08047
07 Feb 22:13
by Sato T
Chemical synthesis of transmembrane peptide and its application for research on the transmembrane-juxtamembrane region of membrane protein.
Biopolymers. 2016 Nov 04;106(4):613-21
Authors: Sato T
Abstract
Membrane proteins possess one or more hydrophobic regions that span the membrane and interact with the lipids that constitute the membrane. The interactions between the transmembrane (TM) region and lipids affect the structure and function of these membrane proteins. Molecular characterization of synthetic TM peptides in lipid bilayers helps to understand how the TM region participates in the formation of the structure and in the function of membrane proteins. The use of synthetic peptides enables site-specific labeling and modification and allows for designing of an artificial TM sequence. Research involving such samples has resulted in significant increase in the knowledge of the mechanisms that govern membrane biology. In this review, the chemical synthesis of TM peptides has been discussed. The preparation of synthetic TM peptides is still not trivial; however, the accumulated knowledge summarized here should provide a basis for preparing samples for spectroscopic analyses. The application of synthetic TM peptides for gaining insights into the mechanism of signal transduction by receptor tyrosine kinase (RTK) has also been discussed. RTK is a single TM protein and is one of the difficult targets in structural biology as crystallization of the full-length receptor has not been successful. This review describes the structural characterization of the synthetic TM-juxtamembrane sequence and proposes a possible scheme for the structural changes in this region for the activation of ErbBs, the epidermal growth factor receptor family. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 106: 613-621, 2016.
PMID: 26573237 [PubMed - indexed for MEDLINE]
15 Jun 18:38
by Nick Cox, James R. Kintzing, Mark Smith, Gerald A. Grant, Jennifer R. Cochran
Abstract
Antibody–drug conjugates (ADCs) offer increased efficacy and reduced toxicity compared to systemic chemotherapy. Less attention has been paid to peptide–drug delivery, which has the potential for increased tumor penetration and facile synthesis. We report a knottin peptide–drug conjugate (KDC) and demonstrate that it can selectively deliver gemcitabine to malignant cells expressing tumor-associated integrins. This KDC binds to tumor cells with low-nanomolar affinity, is internalized by an integrin-mediated process, releases its payload intracellularly, and is a highly potent inhibitor of brain, breast, ovarian, and pancreatic cancer cell lines. Notably, these features enable this KDC to bypass a gemcitabine-resistance mechanism found in pancreatic cancer cells. This work expands the therapeutic relevance of knottin peptides to include targeted drug delivery, and further motivates efforts to expand the drug-conjugate toolkit to include non-antibody protein scaffolds.
Tied up in knottins: Tumor-targeted knottin peptide-drug conjugates (KDC) are significantly smaller than antibody–drug conjugates, allowing for facile synthesis and conjugation. A KDC bearing the nucleoside gemcitabine is internalized by an integrin-mediated mechanism, releases its payload intracellularly, and is shown to be a highly potent inhibitor of several malignant cell lines.
03 Jun 16:53
by Fanpeng Kong, Ziye Liang, Dongrui Luan, Xiaojun Liu, Kehua Xu and Bo Tang

Analytical Chemistry
DOI: 10.1021/acs.analchem.6b01135
31 May 19:44
by Chong Wang, Boran Han, Ruobo Zhou, Xiaowei Zhuang
Real-time imaging of translation activities on individual mRNAs in live cells enables the detection of transient translational responses to environmental stresses, motion dynamics of individual polysomes at different subcellular compartments, and local translation and active transport of polysomes in the dendrites of neurons.
31 May 19:33
by Keith Pardee, Alexander A. Green, Melissa K. Takahashi, Dana Braff, Guillaume Lambert, Jeong Wook Lee, Tom Ferrante, Duo Ma, Nina Donghia, Melina Fan, Nichole M. Daringer, Irene Bosch, Dawn M. Dudley, David H. O’Connor, Lee Gehrke, James J. Collins
A diagnostic platform utilizing biomolecular sensors and CRISPR-based technology allows rapid, specific, and low-cost detection of the Zika virus at clinically relevant concentrations.
21 Apr 17:47
by Lukas Boge, Helena Bysell, Lovisa Ringstad, David Wennman, Anita Umerska, Viviane Cassisa, Jonny Eriksson, Marie-Laure Joly-Guillou, Katarina Edwards and Martin Andersson

Langmuir
DOI: 10.1021/acs.langmuir.6b00338
21 Apr 17:45
by Jun Li, Xuxin Fan, Elena N. Kitova, Chunxia Zou, Christopher W. Cairo, Luiz Eugenio, Kenneth K. S. Ng, Zi Jian Xiong, Gilbert G. Privé and John S. Klassen

Analytical Chemistry
DOI: 10.1021/acs.analchem.6b00043
21 Apr 17:41
by Cong Wei, Guodong Zhang, Tracey Clark, Frank Barletta, L. Nathan Tumey, Brian Rago, Steven Hansel and Xiaogang Han

Analytical Chemistry
DOI: 10.1021/acs.analchem.6b00976
21 Apr 17:41
by Christian D. Ahrberg, Andreas Manz and Pavel Neužil

Analytical Chemistry
DOI: 10.1021/acs.analchem.6b00278
15 Apr 14:34
by Shota Katayama, Tetsuo Moriguchi, Naoki Ohtsu, Toru Kondo
Abstract
Targeted transcriptional activation of endogenous genes is important for understanding physiological transcriptional networks, synthesizing genetic circuits, and inducing cellular phenotype changes. The CRISPR/Cas9 system has great potential to achieve this purpose, however, it has not yet been successfully used to efficiently activate endogenous genes and induce changes in cellular phenotype. A powerful method for transcriptional activation by using CRISPR/Cas9 was developed. Replacement of a methylated promoter with an unmethylated one by CRISPR/Cas9 was sufficient to activate the expression of the neural cell gene OLIG2 and the embryonic stem cell gene NANOG in HEK293T cells. Moreover, CRISPR/Cas9-based OLIG2 activation induced the embryonic carcinoma cell line NTERA-2 to express the neuronal marker βIII-tubulin.
Epigenome editing: A novel CRISPR/Cas9-based method for transcriptional activation through microhomology-mediated end-joining (MMEJ) was developed. CRISPR/Cas9 was used to specifically replace the methylated promotor region of a target gene with an unmethylated copy, thereby leading to efficient gene activation at levels sufficient to bring about changes in cell fate.